期刊
EXPERT OPINION ON EMERGING DRUGS
卷 16, 期 2, 页码 309-322出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2011.537824
关键词
autoimmune; biologics; immunosuppression; inflammation; uveitis
资金
- NEI
Areas covered: This review describes the current and future treatments of uveitis. A literature search was performed in PUBMED from 1965 to 2010 on drugs treating ocular inflammation with emphasis placed on more recent, larger studies. Readers should gain a basic understanding of current treatment strategies beginning with corticosteroids and transitioning to steroid sparing agents. Steroid sparing agents include antimetabolites such as methotrexate, azathioprine and mycophenolate mofetil; calcineurin inhibitors which include cyclosporine, tacrolimus; alkylating agents which include cyclophosphamide and chlorambucil; and biologics which include the TNF-alpha alpha inhibitors infliximab, adalimumab and etanercept and daclizumab, IFN-alpha alpha(2a) and rituximab. Expert opinion: Newer agents are typically formulated from existing drugs or developed based on new advances in immunology. Future treatment will require a better understanding of the mechanisms involved in autoimmune diseases and better delivery systems in order to provide targeted treatment with minimal side effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据